Purpose: F-18 fluorodeoxyglucose (FDG) may accumulate at sites of inflammation or
infection, making interpretation of whole-body scans difficult in patients with cancer …

[18 F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) is a promising
imaging procedure for detecting primary and metastatic cancer in the lungs. We have …

Whole-body PET imaging with 18F-fluorodeoxyglucose (FDG) has been shown to be
effective indistinguishing benign and malignant pulmonary disease. Mildelevations in FDG …

FDG PET is well recognized for its utility in cancer workup. Nonetheless, the differentiation
between malignant and benign pulmonary lesions by FDG PET is challenging. The authors …

Study objectives 18F-fluorodeoxyglucose (FDG) is the most widely used positron emission
tomography (PET) imaging probe used for the diagnosis, staging, restaging, and monitoring …

Radiographic imaging techniques have proved to be of limited value in characterizing chest
masses. Likewise, scintigraphic techniques with tumor-seeking single photon emitting …

Purpose Whole-body fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission
tomography (PET) scanning has been useful in the management of breast cancer. However …

Glycolysis is increased in tumor tissues.[18F] fluoro-2-deoxy-D-glucose (FDG) is a glucose
analogue radiopharmaceutical used in positron emission tomography (PET) to trace glucose …

The D-glucose analogue 2-(fluorine-18) fluoro-2-deoxy-D-glucose (FDG) is the most
commonly used radionuclide in positron emission tomography (PET) of the thorax …

Objective: Positron emission tomography (PET), when used with the intravenously
administered radiopharmaceutical F-18 fluorodeoxyglucose (FDG), has the potential to help …